appScorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Wanbury Ltd
WANBURY
Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Wanbury Limited is a pharmaceutical company which offers active pharmaceutical ingredient in over 70 countries.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
High Pledged Promoter HoldingLower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Press Release
Wanbury Limited has informed the Exchange regarding a press release dated September 09, 2024, titled "Press Release - Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API)". | Download
Wanbury Limited has informed the Exchange regarding a press release dated September 09, 2024, titled "Press Release - Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API)". | Download
Cash Dividend
Final • Div/Share: ₹ 1
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant